Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LunaRx vs REMEVi

LunaRx
Graded #299

Lower grade

vs+12.299999999999997
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 61.2/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +3
54
57
Dose & formulationREMEVi +31
52
83
Clinical oversightREMEVi +4
82
86
Labs & monitoringREMEVi +1
54
55
FulfillmentREMEVi +27
70
97
Contract termsREMEVi +14
55
69
LunaRx · left barREMEVi · right bar

The numbers

MetricLunaRxREMEVi
WeighScore61.2/10073.5/100
GradeCC
Scorecard rank#299#70
Semaglutide$199/mo (starting dose, compounded)$219/mo
TirzepatideNot disclosed$319/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
LunaRx

Graded #299 · C

Strengths

  • Pairs GLP-1 with muscle-protective peptides (e.g., CJC-1295/Ipamorelin, NAD+) to defend lean mass during fat loss
  • Structured, physician-directed off-ramp taper with GI-reset support instead of an indefinite prescription
  • Bilingual care in English and Spanish across intake, messaging, and consults
  • Care directed through a named independent medical group (CareNexus Clinic PC); $0 charged if you are not approved
  • Published clinical support hours (Mon–Fri, CT) with phone, email, and secure messaging; cancel anytime

Where it loses points

  • Only a "from $199/mo" starting price is published; tirzepatide and per-tier pricing are confirmed only after a provider review
  • Compounding pharmacy partners are not named on the site — a transparency gap
  • No LegitScript or PCAB verification is displayed
  • States served are not published; the site claims "telehealth nationwide" but the Terms limit service to states where LunaRx is licensed
  • Compounded medications are not FDA-approved (the site discloses this)
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard